Inhibition of GSK-3β as a target for cardioprotection: the importance of timing, location, duration and degree of inhibition
- 10 June 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Targets
- Vol. 9 (3) , 447-456
Abstract
Cardiovascular disease is the major cause of morbidity and mortality in western countries such as the US. Myocardial infarction leads to loss of myocytes and with extremely limited ability to replenish cardiomyocytes, the heart exhibits depressed contractility. This ultimately results in hypertrophy of the remaining viable myocytes, which is the primary predictor for heart failure. Thus, drug therapies which can reduce myocyte cell death and reduce postischaemic dysfunction would be expected to greatly reduce cardiac hypertrophy and subsequent heart failure and death. Inhibition of glycogen synthase kinase (GSK)-3β has been proposed as a strategy to improve postischaemic cardiomyocyte survival, as inhibition of GSK-3β has been shown to reduce myocardial cell death following ischaemia and reperfusion. Therapies for inhibiting GSK are feasible as there are a number of newly developed specific inhibitors of GSK available, although most of these drugs have not been tested in long-term animal studies.Keywords
This publication has 73 references indexed in Scilit:
- Statins inhibit reoxygenation-induced cardiomyocyte apoptosis: role for glycogen synthase kinase 3β and transcription factor β-cateninJournal of Molecular and Cellular Cardiology, 2004
- Adrenomedullin Protects Against Myocardial Apoptosis After Ischemia/Reperfusion Through Activation of Akt-GSK SignalingHypertension, 2004
- Balancing Contractility and Energy Production: The Role of Myocyte Enhancer Factor 2 (MEF2) in Cardiac HypertrophyRecent Progress in Hormone Research, 2004
- Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation eventBiochemical Journal, 2004
- Rapid accumulation of Akt in mitochondria following phosphatidylinositol 3‐kinase activationJournal of Neurochemistry, 2003
- A-Kinase Anchoring Protein AKAP220 Binds to Glycogen Synthase Kinase-3β (GSK-3β) and Mediates Protein Kinase A-dependent Inhibition of GSK-3βJournal of Biological Chemistry, 2002
- Dual Regulation of Glycogen Synthase Kinase-3β by the α1A-Adrenergic ReceptorJournal of Biological Chemistry, 2001
- A GSK3‐binding peptide from FRAT1 selectively inhibits the GSK3‐catalysed phosphorylation of Axin and β‐cateninFEBS Letters, 1999
- The α‐isoform of glycogen synthase kinase‐3 from rabbit skeletal muscle is inactivated by p70 S6 kinase or MAP kinase‐activated protein kinase‐1 in vitroFEBS Letters, 1994
- Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinaseNeuroscience Letters, 1992